Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2023-06-15 Capital/Financing Update
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Podpisanie aneksów do istotnych umów pożyczek - Content (PL)
Capital/Financing Update Classification · 95% confidence The document text, written in Polish, discusses the amendment (aneks) of significant loan agreements between the Issuer (Pharmena S.A.) and related parties (a leading shareholder and members of management/supervisory boards). The amendments concern extending the repayment date and changing the interest rate calculation method (from fixed to variable based on WIBOR). This type of disclosure, detailing changes in financing arrangements, especially with related parties, falls under updates on the company's capital structure or financing activities. Given the specific definitions, 'Capital/Financing Update' (CAP) is the most appropriate category, as it directly relates to material changes in debt instruments and financing terms. It is not an earnings release (ER), a general regulatory filing (RNS), or a management discussion (MDA), but a specific disclosure about financing terms.
2023-06-15 Polish
PHR_Wykaz akcjonariuszy posiad. pow. 5% głosów na ZWZ w dniu 13 06 2023
Major Shareholding Notification Classification · 99% confidence The document is titled 'Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Pharmena S.A. w dniu 13.06.2023 r.', which translates to 'List of shareholders holding at least 5% of the votes at the Annual General Meeting of Pharmena S.A. on 13.06.2023'. This content explicitly details the voting power distribution among major shareholders during a specific General Meeting. This directly aligns with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting (AGM or EGM). The document is a direct result/record of the voting process, not a presentation (AGM-R) or a proxy solicitation (PSI).
2023-06-15 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ w dniu 13.06.2023 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text is very short (383 characters) and explicitly states that the management ('Zarząd PHARMENA S.A.') is attaching a list ('wykaz akcjonariuszy') of shareholders holding at least 5% of the votes from the Annual General Meeting ('Zwyczajnym Walnym Zgromadzeniu') held on 13.06.2023. This content—a specific announcement regarding voting results or shareholder structure following a meeting—fits best under Declaration of Voting Results & Voting Rights Announcements (DVA), as it details the outcome/structure related to voting rights post-meeting. It is not the full AGM presentation (AGM-R) or a general regulatory filing (RNS), but a specific declaration related to voting outcomes.
2023-06-15 Polish
230613_PHR_Informacje o Członkach RN
Board/Management Information Classification · 98% confidence The document text provides detailed biographical and professional information for several individuals (Jacek Dauenhauer, Agnieszka Dziki, Jerzy Gębicki, Anna Janicka) who have been appointed as members of the Supervisory Board ('Rada Nadzorcza'). The structure, content (listing appointment date, function, education, prior roles, and other activities), and the reference to Polish regulations concerning information disclosed by issuers strongly indicate this is a mandatory disclosure regarding changes or appointments to the Board of Directors or Supervisory Board. This aligns perfectly with the definition for Board/Management Information (MANG): 'Announcement of changes in the company's board of directors or senior management.' It is not a general Annual Report (10-K), an Earnings Release (ER), or a proxy statement (DEF 14A/PSI).
2023-06-14 Polish
Powołanie członków Rady Nadzorczej na nową kadencję - Content (PL)
Board/Management Information Classification · 98% confidence The document text, written in Polish, announces the results of the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie) held on June 13, 2023. Specifically, it details the resolution (uchwałę nr 15) regarding the appointment of the members of the Supervisory Board (Rady Nadzorczej) for a new term. This directly relates to changes in the company's governing body structure. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. Although it is related to an AGM, the core content is the resulting board appointments, not the general AGM proceedings or voting results themselves, making MANG the most precise fit over AGM-R or DVA.
2023-06-14 Polish
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 13 06 2023
AGM Information Classification · 98% confidence The document text is titled "Uchwały podjęte przez Zwyczajne Walne Zgromadzenie" (Resolutions adopted by the Annual General Meeting) and details several resolutions (Uchwała nr 1 through nr 7) passed on June 13, 2023, concerning the approval of annual reports, financial statements (individual and consolidated) for the period ending 12/31/2022, and the granting of discharge (absolutorium) to a board member. The content explicitly deals with the formal outcomes and resolutions of an Annual General Meeting (AGM). This strongly indicates the document is related to the AGM proceedings and results. The most appropriate classification is AGM-R (AGM Information), as it contains the resolutions passed during that meeting.
2023-06-14 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.